1-3 of 3
Mary Tran
Close
Sort by
Journal Articles

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

Jennifer O. Lauchle, MD, Doan T. Le, MD, Doris Kim, Keiko Akagi, PhD, Matthew F. Gorman, MD, Mary Tran, Judith Sebolt-Leopold, PhD, Linda Wolff, PhD, Luis F. Parada, PhD, Nancy Jenkins, PhD, Neal Copeland, PhD, Kevin M. Shannon, MD
Journal: Blood
Blood (2007) 110 (11): 594.
https://doi.org/10.1182/blood.V110.11.594.594
Published: 2007
Journal Articles

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

Dharminder Chauhan, Paola Neri, Mugdha Velankar, Klaus Podar, Teru Hideshima, Mariateresa Fulciniti, Pierfrancesco Tassone, Noopur Raje, Constantine Mitsiades, Nicholas Mitsiades, Paul Richardson, Leigh Zawel, Mary Tran, Nikhil Munshi, Kenneth C. Anderson
Journal: Blood
Blood (2006) 109 (3): 1220–1227.
https://doi.org/10.1182/blood-2006-04-015149
Published: 2006
Journal Articles

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Jennifer O. Lauchle, MD, Doan Le, MD, Doris Kim, BA, Mary Tran, BA, Abigail Peterson, BA, Sally Przybranowski, PhD, Luis Parada, PhD, Linda Wolff, PhD, Judith Leopold, PhD, Kevin M. Shannon, MD
Journal: Blood
Blood (2005) 106 (11): 496.
https://doi.org/10.1182/blood.V106.11.496.496
Published: 2005